Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jeff Shuren Talks Breakthrough Bonanza, TPLC And Innovating Safety

Executive Summary

In an interview at The MedTech Conference in Philadelphia this week, US FDA device-center Director Jeff Shuren spoke to Medtech Insight about what is happening with the pending total product lifecycle office and the larger-than-expected response to the Breakthrough Devices Program. He also makes the point that supporting innovation and protecting safety are not opposing goals, and more.

Advertisement

Related Content

Into 2019: Digital Leads US Policy Innovations, But Public Medtech Scrutiny Grows
Breathing Easy: ALung CEO Talks Novel Hemolung Device, FDA's Breakthrough Pathway, Landmark US/UK Clinical Trials
Alzheimer's Is A Repeat Target For FDA Breakthrough Device Path
CMS Actively Looking For New Reimbursement Pathway For Innovative Devices

Topics

Advertisement
UsernamePublicRestriction

Register

MT123338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel